Advances in Psoriasis

A Multisystemic Guide

Häftad, Engelska, 2021

1 229 kr

Beställningsvara. Skickas inom 10-15 vardagar

Fri frakt för medlemmar vid köp för minst 249 kr.

This extensively revised second edition provides an up-to-date and highly informative textbook on psoriasis. The understanding of the mechanisms behind the disease and the available treatment options have continued to develop rapidly in recent times, with this vital resource covering the latest in these management options, including targeted T-cell therapy, the use of immunomodulators, systemic therapies, and ultraviolet and laser therapy. In addition, it provides a detailed overview of the pathophysiology, comorbidities, epidemiology and triggers of the disease.Advances in Psoriasis: A Multisystemic Guide extensively details the scientific basis and practice management of psoriasis. It is therefore a vital resource for practicing and trainee dermatologists looking to develop their clinical knowledge of how to manage and treat these patients.

Produktinformation

Utgivningsdatum2021-11-27
Mått178 x 254 x undefined mm
FormatHäftad
SpråkEngelska
Antal sidor423
Upplaga2
FörlagSpringer Nature Switzerland AG
ISBN9783030548612

Tillhör följande kategorier

Onkologi inom Medicin
Sjukdomar och rubbningar inom Medicin
Dermatologi inom Medicin
Behandling och behandlingsmetoder inom Medicin

Dr. Weinberg, is an Associate Clinical Professor of Dermatology at Mount Sinai School of Medicine, New York. In addition, he is director of the Clinical Research Center/Dermatopharmacology at St. Luke’s-Roosevelt Hospital Center and acting director of the Division of Dermatology at Jamaica Hospital Medical Center, both in New York City. Prior to this he was an Assistant Clinical Professor of Dermatology at Columbia University College of Physicians and Surgeons in New York City. Dr. Weinberg graduated from the University of Pennsylvania School of Medicine in Philadelphia and completed an internship in medicine at Columbia-Presbyterian Medical Center in New York City. He then completed a residency in dermatology at the University of Pennsylvania School of Medicine. He is a fellow of the American Academy of Dermatology, where he has served on several committees, and a member of the Dermatology Foundation. He is a diplomat of the American Board of Dermatology. Dr. Lebwohl graduated from Columbia University in 1974. He earned his medical degree from Harvard Medical School in 1978 and subsequently completed residencies in both internal medicine and dermatology at the Icahn School of Medicine at Mount Sinai. In 1983, he was made Assistant Professor of Dermatology at Mount Sinai. In 1997, he was named Chairman of the Department which, under his leadership, has been at the forefront of the management of psoriasis. He was the first to report the cardiac complications of pseudoxanthoma elasticum, and, additionally, he has developed new techniques for diagnosing the disease. He was also the first to use immunomodulators (imiquimod) to treat preccancerous skin lesions, the first to use topical calcineurin inhibitors to treat psoriasis, and the first to identify interactions between topical vitamin D analogues such as calcipotriol and calcitriol with other topical medications and with ultraviolet light. He has been at the forefront of clinical trials for new biologic therapies for psoriasis.

Introduction to and History of Psoriasis and Psoriasis Therapy.- Pathophysiology of Psoriasis/Novel Pathways.- Psoriasis: Clinical Review and Update.- Psoriasis: Epidemiology, Potential Triggers, Disease Course.- Topical Therapy I: Corticosteroids and Vitamin D Analogues.- Topical Therapy II: Retinoids, Immunomodulators, and Others.- Topical Therapy II: Retinoids, Immunomuodulators, and Others/ Ultraviolet Therapy for Psoriasis.- Laser Therapy for Psoriasis.- Traditional Systemic Therapy I: Methotrexate and Cyclosporine.- Traditional Systemic Therapy II: Retinoids and Others.- Apremilast.- Etanercept.- Adalimumab.- Infliximab, Golimumab , and Certolizumab Pegol.- Ustekinumab.- Guselkumab.- Tidrakizumab.- Risankizumab.- Secukinumab.- Ixekizumab.- Brodalumab.- Biosimilars for Psoriasis.- Research Pipeline I: Oral Therapeutics for Psoriasis.- Research Pipeline II: Upcoming Biologic Therapies.- Pediatric Psoriasis.- Challenges in Psoriasis Treatment: Nail, Scalp, and Palmoplantar Involvement.- Psoriasis and Comorbidities.- Summary of Published Treatment Guidelines.- Index.